UNION therapeutics

UNION therapeutics announces positive topline results from the OSIRIS investigator-initiated proof-of-concept study of oral orismilast in patients with hidradenitis suppurativa

by

Study demonstrates clinically relevant improvements in patients with hidradenitis suppurativa (HS) receiving 16 weeks of treatment with oral orismilast Study supports the dose-finding results from the recent IASOS Phase 2b study of oral orismilast in psoriasis Orismilast has been granted a Fast Track designation by the FDA for HS, and UNION plans to seek regulatory … Read more

UNION therapeutics announces positive topline results from the OSIRIS investigator-initiated proof-of-concept study of oral orismilast in patients with hidradenitis suppurativa USA – English USA – English

by

Study demonstrates clinically relevant improvements in patients with hidradenitis suppurativa (HS) receiving 16 weeks of treatment with oral orismilast Study supports the dose-finding results from the recent IASOS Phase 2b study of oral orismilast in psoriasis Orismilast has been granted a Fast Track designation by the FDA for HS, and UNION plans to seek regulatory … Read more